Albert David Limited will hold a board meeting on 12 Nov 2026 to consider unaudited financial results for the quarter and half year ended September 2026. The trading window is already closed from 01 Oct 2026 and reopens 48 hours after results.
Albert David Limited submitted the minutes of its 87th Annual General Meeting held on August 6, 2026. The meeting successfully concluded the proposed agenda items.
Albert David Limited conducted its 87th Annual General Meeting via video conferencing. The meeting covered adoption of financial statements, dividend declaration, and various director appointments.
Albert David Limited has scheduled a board meeting on August 6, 2026, to consider and approve its unaudited financial results for the quarter ended June 30, 2026.
Albert David Limited has scheduled its 87th Annual General Meeting for August 6, 2026. The company also released its Annual Report for fiscal year 2025-2026.
Albert David Ltd announced the resignation of Cluster Head Mr. Saikath Banerjee, effective July 4, 2026. His departure marks a change in senior management for the company.
Albert David Limited announced the resignation of Mr. Chandra Bhushan Thakur as Head-Operations (Ghaziabad). The departure was effective from May 29, 2026, due to personal reasons.
Albert David Limited submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report indicates no material non-compliances or regulatory penalties.
Albert David Limited appointed Amit Mahla as Chief Executive Officer effective May 12, 2026. He brings 28 years of pharmaceutical leadership experience from JB Pharma and Cipla.
Albert David Limited reported annual Total Income of ₹341.05 Crore for FY2025-26. The board approved results on May 12, 2026, with an unmodified audit opinion.